Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma
This is a multicenter prospective single arm phase II study. The purpose of this study is to evaluate the safety and efficiency of azacytidine combined with chidamide in the treatment of relapsed/refractory angioimmunoblastic T-cell lymphoma.
Angioimmunoblastic T-cell Lymphoma
DRUG: Azacitidine|DRUG: Chidamide
Overall Response Rate (ORR), ORR was defined as the proportion of patients who achieved CR or PR as their best response, 1year
progression-free survival (PFS), PFS was defined as time from diagnosis to the date of disease progression or death from any cause or the last follow-up., 1 year|Duration of response (DOR), DOR was defined as the time from the first occurrence of CR or PR to the first diagnosis of PD or relapse., through study completion, an average of 1 year|overall survival (OS), OS was defined as time from diagnosis to death from any cause or the last follow-up., through study completion, an average of 2 year|Adverse Events, Graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, During the whole treatment
Azacytidine was given subcutaneously at a dose of 75 mg/m2 on days 1-7. Chidamide was an oral tablet which was administered 20mg twice weekly. This regimen was repeated every 28 days. Treatment was given until disease progression, unacceptable toxicity, or patient/investigator discretion.